[4-(2-bromo-ethoxy)-phenyl]-acetic acid | 59127-37-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: [4-(2-bromo-ethoxy)-phenyl]-acetic acid
• 英文别名: [4-(2-Brom-aethoxy)-phenyl]-essigsaeure；4-(2-bromoethoxy)-phenylacetic acid；2-[4-(2-bromoethoxy)phenyl]acetic acid
• CAS: 59127-37-6
• 化学式: C₁₀H₁₁BrO₃
• 分子量: 259.1
• InChiKey: WNMSWTYGDNNRIM-UHFFFAOYSA-N

物化性质

• 熔点：
  108-110 °C
• 沸点：
  385.5±27.0 °C(Predicted)
• 密度：
  1.519±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  [4-(2-bromo-ethoxy)-phenyl]-acetic acid 生成 [4-(2-dimethylamino-ethoxy)-phenyl]-acetic acid-(2-dimethylamino-ethyl ester)
  参考文献：
  名称：

  The localization of type 2 diabetes susceptibility gene loci in northern Chinese Han families

  摘要：

  We conducted a genome-wide scan, in which 358 well distributed fluorescent dye-labeled microsatellite marker sets were applied in 32 Chinese Han type 2 diabetes families from Northern China to search for the susceptibility gene loci. The data collected from screening all the chromosomes of genome were genotyped by using genescan and genotyping software, then, parametric and non-parametric multipoint test, and affected sib-pair analysis as well, were used to analyze the data. We identified some susceptibility gene loci residing in chromosomes 1,12,18,20, respectively, or precisely, located around D1S214, D1S207, D1S218, D1S235, D12S336, D18S61 and D20S118. The comparison of this result with those from other regions and races reflected the complexity and heterogeneity of type 2 diabetes.

  DOI：

  10.1007/bf02886269
• 作为产物：
  描述：

  4-羟基苯乙酸甲酯 在 sodium hydroxide 、 potassium carbonate 作用下， 以 甲醇 、 乙腈 为溶剂， 反应 12.0h， 生成 [4-(2-bromo-ethoxy)-phenyl]-acetic acid
  参考文献：
  名称：

  Synthesis and Biological Evaluation of Phenylacetyl Derivatives Having Low Central Nervous System Permeability as Potent and Selective M2 Muscarinic Receptor Antagonists.

  摘要：

  一系列含有5,10-二氢-11H-二苯并[b,e][1,4]二氮杂卓-11-酮或5,11-二氢-6H-吡啶并[2,3-b][1,4]苯并二氮杂卓-6-酮骨架的苯乙酰基衍生物被制备并评估了它们与毒蕈碱受体在体外的结合亲和力以及对心动过缓、唾液分泌和震颤的体内拮抗作用。其中，化合物56和66对心脏中的M2毒蕈碱受体具有高亲和力（pKi分别为8.7和8.9），而对颌下腺中的M3毒蕈碱受体的亲和力较低。结构-活性关系（SAR）研究表明，56对M2受体的高选择性可能是由于酰胺羰基的定向。在体内研究中，56和66均能拮抗氧颤药引起的大鼠心动过缓，无论是静脉注射还是口服给药，且它们对夜间心动过缓的狗的心率增加效果是AF-DX 116的3倍左右。此外，它们对氧颤药引起的小鼠震颤几乎没有影响，无证据表明中枢转移。

  DOI：

  10.1248/cpb.46.53

文献信息

• Synthesis and Biological Evaluation of Phenylacetyl Derivatives Having Low Central Nervous System Permeability as Potent and Selective M2 Muscarinic Receptor Antagonists.
  作者：Toshihiro WATANABE、Akio KAKEFUDA、Akihiro TANAKA、Kenji TAKIZAWA、Seiko HIRANO、Hiroshi SHIBATA、Yoko YAMAGIWA、Isao YANAGISAWA

  DOI：10.1248/cpb.46.53

  日期：——

  A series of phenylacetyl derivatives containing the 5, 10-dihydro-11H-dibenzo[b, e][1, 4]diazepin-11-one or 5, 11-dihydro-6H-pyrido[2, 3-b][1, 4]benzodiazepin-6-one skeleton was prepared and evaluated for their binding affinities to muscarinic receptors in vitro and for antagonism of bradycardia, salivation and tremor in vivo. Among them, compounds 56 and 66 had high affinity for M2 muscarinic receptors in the heart (pKi=8.7 and 8.9, respectively) with low affinity for M3 muscarinic receptors in the submandibular gland. A structure-activity relationship (SAR) study suggested that the high M2 selectivity over the M3 muscarinic receptors of 56 may be attributed to the direction of the carboxamide carbonyl group. In in vivo studies, 56 and 66 antagonized oxotremorine-induced bradycardina in rats on both intravenous and oral administration, and their heart rate increasing effect in dogs with nocturnal bradycardia was about 3-fold greater than that of AF-DX 116. Furthermore, they had almost no influence on oxotremorine-induced tremor in mice, presenting no evidence of central transfer.

  一系列含有5,10-二氢-11H-二苯并[b,e][1,4]二氮杂卓-11-酮或5,11-二氢-6H-吡啶并[2,3-b][1,4]苯并二氮杂卓-6-酮骨架的苯乙酰基衍生物被制备并评估了它们与毒蕈碱受体在体外的结合亲和力以及对心动过缓、唾液分泌和震颤的体内拮抗作用。其中，化合物56和66对心脏中的M2毒蕈碱受体具有高亲和力（pKi分别为8.7和8.9），而对颌下腺中的M3毒蕈碱受体的亲和力较低。结构-活性关系（SAR）研究表明，56对M2受体的高选择性可能是由于酰胺羰基的定向。在体内研究中，56和66均能拮抗氧颤药引起的大鼠心动过缓，无论是静脉注射还是口服给药，且它们对夜间心动过缓的狗的心率增加效果是AF-DX 116的3倍左右。此外，它们对氧颤药引起的小鼠震颤几乎没有影响，无证据表明中枢转移。
• Compounds and methods for modulation of estrogen receptors
  申请人：Signal Pharmaceuticals, Inc.

  公开号：US06436923B1

  公开（公告）日：2002-08-20

  Compounds that modulate the estrogen receptor (ER) are disclosed, as well as pharmaceutical compositions containing the same. In a specific embodiment, the compounds are selective modulators for ER-&bgr; over ER-&agr;. Methods are disclosed for modulating ER-&bgr; in cell and/or tissues expressing the same, including cells and/or tissue that preferentially express ER-&bgr;. More generally, methods for treating estrogen-related conditions are also disclosed, including conditions such as is breast cancer, testicular cancer, osteoporosis, endometriosis, cardiovascular disease, hypercholesterolemia, prostatic hypertrophy, prostatic carcinomas, obesity, hot flashes, skin effects, mood swings, memory loss, urinary incontinence, hairloss, cataracts, natural hormonal imbalances, and adverse reproductive effects associated with exposure to environmental chemicals.

  揭示了调节雌激素受体（ER）的化合物，以及含有这些化合物的药物组合物。在一个特定实施例中，这些化合物是选择性调节ER-β而不是ER-α的调节剂。还揭示了调节在表达同样的细胞和/或组织中的ER-β的方法，包括优先表达ER-β的细胞和/或组织。更一般地，还揭示了治疗与雌激素相关疾病的方法，包括乳腺癌、睾丸癌、骨质疏松症、子宫内膜异位症、心血管疾病、高胆固醇血症、前列腺肥大、前列腺癌、肥胖、潮热、皮肤影响、情绪波动、记忆丧失、尿失禁、脱发、白内障、天然激素失衡以及与暴露于环境化学物质相关的不良生殖影响。
• A nonhydrolyzable analogue of phosphotyrosine, and related aryloxymethano- and aryloxyethano-phosphonic acids as motifs for inhibition of phosphatases
  作者：Subashree Iyer、Jarod M. Younker、Przemyslaw G. Czyryca、Alvan C. Hengge

  DOI：10.1016/j.bmcl.2004.09.008

  日期：2004.12

  Nonhydrolyzable analogues of both stereoisomers of phosphotyrosine, and a series of related aryloxy (or thio) methyl and aryloxy (or thio) ethyl phosphonic acids of the general formula RX-(CH2) -PO3H2 (where X = O or S and n = 1 or 2), have been tested as nonhydrolyzable mimetics of phosphatase substrates. These compounds were tested against a panel of phosphatases (two alkaline phosphatases, a protein-tyrosine phosphatase, and two serine/threonine phosphatases) with different active site motifs. The compounds exhibit competitive inhibition toward all enzymes tested, with the best inhibition expressed toward the Ser/Thr phosphatases. The stereoisomers of the phosphotyrosine analogues exhibited an unexpected difference in their inhibitory properties toward the protein-tyrosine phosphatase from Yersinia. The K-i for the D isomer is 33-fold lower than that of the (L) isomer, and is more than an order of magnitude lower than the reported K, of the substrate L-phosphotyrosine. (C) 2004 Elsevier Ltd. All rights reserved.
• COMPOUNDS AND METHODS FOR MODULATION OF ESTROGEN RECEPTORS
  申请人：SIGNAL PHARMACEUTICALS, INC.

  公开号：EP1163225A1

  公开（公告）日：2001-12-19
• US6436923B1
  申请人：——

  公开号：US6436923B1

  公开（公告）日：2002-08-20